| scholarly article | Q13442814 |
| P50 | author | Jürgen Burhenne | Q37382570 |
| Gerd Mikus | Q37382592 | ||
| Walter E Haefeli | Q38641417 | ||
| P2093 | author name string | Klaus-Dieter Riedel | |
| Johanna Weiss | |||
| Heike Oberwittler | |||
| Ina Scholz | |||
| P2860 | cites work | Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans | Q24323988 |
| Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese | Q28241420 | ||
| The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans | Q28254348 | ||
| Metabolic characterization of the major human small intestinal cytochrome p450s | Q31957374 | ||
| Voriconazole -- better chances for patients with invasive mycoses. | Q34691709 | ||
| Development and validation of a high-performance liquid chromatography assay for voriconazole | Q39776152 | ||
| No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers | Q41921748 | ||
| Effect of omeprazole on the steady‐state pharmacokinetics of voriconazole | Q42144423 | ||
| A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants | Q42168063 | ||
| Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration | Q42760098 | ||
| CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole | Q44273424 | ||
| Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole | Q44403610 | ||
| The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human | Q44447139 | ||
| Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status | Q44923012 | ||
| Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations | Q46141212 | ||
| Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics | Q46589222 | ||
| Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population. | Q50953435 | ||
| Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir | Q56829869 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | voriconazole | Q412236 |
| bioavailability | Q461809 | ||
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 906-915 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype | |
| P478 | volume | 68 |
| Q64245308 | A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis |
| Q57730442 | A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children |
| Q91452393 | A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation |
| Q35936943 | Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. |
| Q38420688 | Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. |
| Q36905195 | Aspergillus flavus-Induced Brain Abscess in an Immunocompetent Child: Case report |
| Q48333024 | Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. |
| Q33849298 | CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? |
| Q35754431 | Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia |
| Q35086478 | Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population. |
| Q57036259 | Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis |
| Q38284468 | Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. |
| Q64235405 | Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections |
| Q41708603 | Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians |
| Q39269082 | Cutaneous Toxicities From Transplantation-Related Medications |
| Q40322487 | Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. |
| Q47425844 | Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. |
| Q57611765 | Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients |
| Q40377329 | Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients |
| Q35114591 | Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy |
| Q43232273 | High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype. |
| Q92613671 | High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness |
| Q26999448 | How to manage aspergillosis in non-neutropenic intensive care unit patients |
| Q46119145 | Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. |
| Q33982372 | Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis |
| Q41392620 | Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole |
| Q40290020 | Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections |
| Q35960842 | In vitro study of the variable effects of proton pump inhibitors on voriconazole |
| Q41986948 | In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates |
| Q42755345 | Increasing the dose of voriconazole compensates for enzyme induction by phenytoin |
| Q93185890 | Integrating anatomo-physiological changes and pharmacogenomics in anti-infective therapy management: is it a major concern? |
| Q43512563 | Interaction between voriconazole and flucloxacillin during treatment of disseminated Scedosporium apiospermum infection |
| Q47649550 | Interpersonal factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 genotypes enough for us to make a clinical decision? |
| Q38661462 | Intravenous-to-oral switch in antimicrobial therapy: clinical pharmacology considerations and perspectives |
| Q39797076 | Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations |
| Q36887922 | Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. |
| Q57162735 | Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole |
| Q36172497 | Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring |
| Q38775809 | Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy |
| Q38918175 | PharmGKB summary: voriconazole pathway, pharmacokinetics |
| Q60046975 | Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit |
| Q34977413 | Pharmacogenomics of antimicrobial agents |
| Q37892536 | Pharmacogenomics of the triazole antifungal agent voriconazole |
| Q47664190 | Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy |
| Q38816614 | Pharmacokinetic considerations in treating invasive pediatric fungal infections |
| Q42966049 | Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring |
| Q38215682 | Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. |
| Q35364006 | Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. |
| Q36764126 | Plasma Voriconazole Estimation by HPLC. |
| Q35231368 | Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. |
| Q34316979 | Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase |
| Q47191846 | Significance of monitoring plasma concentration of voriconazole in a patient with liver failure: A case report |
| Q36969849 | Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation |
| Q59125874 | The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro |
| Q36608562 | Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole |
| Q38526795 | Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review. |
| Q27009221 | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| Q37945308 | Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. |
| Q37964703 | Triazole antifungal agents in invasive fungal infections: a comparative review |
| Q51110220 | Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. |
| Q38061736 | Voriconazole in clinical practice |
| Q33684379 | Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype |
| Q34138276 | Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. |
| Q27012442 | Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients |
| Q53266683 | Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients. |
Search more.